Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

IMPORTANCE: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified t...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:JAMA Oncol
मुख्य लेखकों: Powles, Ryan L., Redmond, David, Sotiriou, Christos, Loi, Sherene, Fumagalli, Debora, Nuciforo, Paolo, Harbeck, Nadia, de Azambuja, Evandro, Sarp, Severine, Di Cosimo, Serena, Huober, Jens, Baselga, Jose, Piccart-Gebhart, Martine, Elemento, Olivier, Pusztai, Lajos, Hatzis, Christos
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Medical Association 2018
विषय:
Brief Report
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224305/
https://ncbi.nlm.nih.gov/pubmed/29902299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1564
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन